London, United Kingdom
Intract Pharma is a dynamic biotechnology company committed to advancing patient care by transforming traditional injectable therapies into oral formulations. Founded in 2016 and headquartered in the United Kingdom, the company is pioneering innovations in the oral delivery of complex proteins, particularly focusing on monoclonal antibodies for treating gastrointestinal and systemic immune-mediated inflammatory diseases.
The company's proprietary Phloral™ and Soteria™ technology platforms are at the forefront of precision medicine, enabling the targeted delivery of proteins to the colon. This approach aims to achieve local tissue and systemic immunomodulation, potentially revolutionizing the treatment landscape for millions suffering from chronic diseases by simplifying their medication regimen into safe and effective pills.
Intract Pharma's mission-oriented strategy of "Transforming Patient Care by Replacing Injections with Safer, More Effective Therapeutics Given Orally" captures its expansive vision and sectoral focus. The company last received a £420.00K grant investment in October 2018, signaling investor confidence in its innovative capabilities.
